The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Bortezomib Biotech Pharma 3.5 mg powder for solution for injection

Target Healthcare LimitedPA25233/001/001

Main Information

Trade NameBortezomib Biotech Pharma 3.5 mg powder for solution for injection
Active SubstancesBortezomib
Dosage FormPowder for solution for injection
Licence HolderTarget Healthcare Limited
Licence NumberPA25233/001/001

Group Information

ATC CodeL01XX32 bortezomib


License statusAuthorised
Licence Issued26/06/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See: Summary of Product Characteristics, section 4.2)
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back